Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Echinacea angustifolia extract is a botanical extract derived from the roots of Echinacea angustifolia (narrow-leaf purple coneflower). It is widely used as a dietary supplement and herbal medicine for immune support, wound healing, and the treatment of upper respiratory tract infections. A specific standardized preparation of the extract, known as EP107, has also been clinically evaluated for its psychotropic effects, particularly in reducing psychic anxiety and stress. The extract's primary active constituents are alkylamides (isobutylamides), echinacoside, and polysaccharides. The alkylamides act as agonists of the cannabinoid CB1 and CB2 receptors, modulating the endocannabinoid system to exert anti-inflammatory, analgesic, and anxiolytic effects. Additionally, the extract stimulates immune cells such as macrophages, granulocytes, and phagocytes, and has demonstrated preclinical cytotoxic activity against breast cancer cell lines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on echinacea angustifolia extract.